Charles River Labs up on biologics services

By Staff Reporter

- Last updated on GMT

Image: iStock/patpitchaya
Image: iStock/patpitchaya

Related tags Contract research organization

Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.

The contract research organisation (CRO) reported its full year 2016 results this week, and attributed its $100m – a 13% year-on-year organic increase – in manufacturing revenues to “robust growth”​ in its microbial solutions and biologics testing business.

“Our continued investment in expanding our biologics portfolio, most recently with the acquisition of Blue Stream​, has enabled us to provide a comprehensive portfolio of both bioanalytical and biosafety testing services, with the ability to support biologic and biosimilar development from discovery through clinical phases and commercial manufacturing,”​ CEO James Foster told investors.

“This has increased the value proposition for our clients. And as demand for our services grows, we have added capacity, especially in the US.”

He added the firm views its biologics business is growing in precedence due to the growing number of biologic drugs in development.

“Our goal is to be well-positioned to capitalize on this expanding opportunity, which we believe will support our growth in the coming years.”

For the full year, Charles River reported total revenue of $1.7bn, up 23% year-on-year. The bottom line too was up 4% to $155m.

Related news

Show more

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers